Clinical Research Directory
Browse clinical research sites, groups, and studies.
Immune Response to Immunotherapy in Lung Cancer: Study of Sputum and Blood Samples
Sponsor: University Hospital, Tours
Summary
Lung cancer is the leading cause of cancer-related death worldwide, with nearly 2.48 million cases and 1.8 million deaths in 2022. Despite therapeutic progress, late diagnosis and high mortality make it a major public health issue. Immune checkpoint inhibitors (ICI) such as nivolumab, pembrolizumab, and atezolizumab have improved outcomes for some patients, but only a small proportion benefit, and side effects can be severe. Research is focusing on combining ICIs with chemotherapy, radiotherapy, or other immunotherapies, but reliable biomarkers to predict responders are still lacking. The tumor microenvironment, which promotes resistance, is a promising therapeutic target. The RICEPS study (2021-2023) found specific immune cells and cytokines linked to treatment response, and the ongoing RICEPS-2 trial aims to confirm these findings in a larger group to better understand immune dynamics in lung cancer under ICI therapy.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2026-04
Completion Date
2028-10
Last Updated
2026-03-18
Healthy Volunteers
Yes
Interventions
Blood sample
Each patient will have a 5-10 ml blood sample taken at M0, M3, and M6.
sputum sample
Each patient will provide a sputum sample at M0, M3, and M6.
Locations (1)
university hospital, Tours
Tours, France